We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
Read MoreHide Full Article
Amgen Inc. (AMGN - Free Report) announced that a three-drug combination regimen of its multiple myeloma (MM) drug Kyprolis improved progression-free survival (PFS) in a phase III study.
The phase III CANDOR study evaluating Amgen's Kyprolis + dexamethasone and Johnson & Johnson's (JNJ - Free Report) Darzalex in patients with relapsed or refractory multiple myeloma, met the primary endpoint of PFS compared to Kyprolis plus dexamethasone (Kd) alone.
In the study, treatment with the three-drug Kyprolis combo (KdD) led to a reduction in the risk of progression or death by 37% in patients with relapsed or refractory MM.
The median PFS for patients who received Kd alone was 15.8 months. However, as of the cut-off date, the median PFS has not been reached for patients in the KdD arm. Also, there were a higher number of adverse events like thrombocytopenia, anemia, diarrhea, hypertension among others reported in the KdD regimen compared to Kd.
Notably, this is the first phase III study, evaluating the combo of Kyprolis and Darzalex for treating the given patient population. The primary endpoint was PFS while the key secondary endpoints were overall response rate, minimal residual disease and overall survival.
The randomized, open-label CANDOR study was initiated by Amgen as part of its collaboration agreement with Janssen, a subsidiary of J&J, which is also co-funding the study along with Amgen.
Amgen plans to present data from the above study at an upcoming medical conference. The company also plans to submit the results for regulatory approvals.
Shares of Amgen have inched up 0.4% so far this year against the industry’s decline of 1.8%.
We remind investors that Kyprolis is already approved as a monotherapy as well as in combination with dexamethasone or Celgene Corporation's Revlimid (lenalidomide) plus dexamethasone for the treatment of relapsed/refractory MM in patients who have received one to three lines of therapy.
During the first half of 2019, Kyprolis generated sales of $512 million, reflecting an increase of 5.6% year over year, primarily driven by volume growth in the United States.
NuCana’s loss per share estimates have been narrowed 17.5% for 2019 and 16.7% for 2020 over the past 60 days.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
Image: Bigstock
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
Amgen Inc. (AMGN - Free Report) announced that a three-drug combination regimen of its multiple myeloma (MM) drug Kyprolis improved progression-free survival (PFS) in a phase III study.
The phase III CANDOR study evaluating Amgen's Kyprolis + dexamethasone and Johnson & Johnson's (JNJ - Free Report) Darzalex in patients with relapsed or refractory multiple myeloma, met the primary endpoint of PFS compared to Kyprolis plus dexamethasone (Kd) alone.
In the study, treatment with the three-drug Kyprolis combo (KdD) led to a reduction in the risk of progression or death by 37% in patients with relapsed or refractory MM.
The median PFS for patients who received Kd alone was 15.8 months. However, as of the cut-off date, the median PFS has not been reached for patients in the KdD arm. Also, there were a higher number of adverse events like thrombocytopenia, anemia, diarrhea, hypertension among others reported in the KdD regimen compared to Kd.
Notably, this is the first phase III study, evaluating the combo of Kyprolis and Darzalex for treating the given patient population. The primary endpoint was PFS while the key secondary endpoints were overall response rate, minimal residual disease and overall survival.
The randomized, open-label CANDOR study was initiated by Amgen as part of its collaboration agreement with Janssen, a subsidiary of J&J, which is also co-funding the study along with Amgen.
Amgen plans to present data from the above study at an upcoming medical conference. The company also plans to submit the results for regulatory approvals.
Shares of Amgen have inched up 0.4% so far this year against the industry’s decline of 1.8%.
We remind investors that Kyprolis is already approved as a monotherapy as well as in combination with dexamethasone or Celgene Corporation's Revlimid (lenalidomide) plus dexamethasone for the treatment of relapsed/refractory MM in patients who have received one to three lines of therapy.
During the first half of 2019, Kyprolis generated sales of $512 million, reflecting an increase of 5.6% year over year, primarily driven by volume growth in the United States.
Zacks Rank & Another Key Pick
Amgen currently sports a Zacks Rank #1 (Strong Buy). Another top-ranked stock in the healthcare sector is NuCana PLC (NCNA - Free Report) , which has the same favorable Zacks Rank as Amgen. You can see the complete list of today’s Zacks #1 Rank stocks here.
NuCana’s loss per share estimates have been narrowed 17.5% for 2019 and 16.7% for 2020 over the past 60 days.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>